Tags

Type your tag names separated by a space and hit enter

IMPACT OF COMORBIDITIES IN MEXICAN SARS-COV-2-POSITIVE PATIENTS: A RETROSPECTIVE ANALYSIS IN A NATIONAL COHORT.
Rev Invest Clin. 2020; 72(3):151-158.RI

Abstract

Background

The coronavirus disease 2019 outbreak is a significant challenge for health-care systems around the world.

Objective

The objective of the study was to assess the impact of comorbidities on the case fatality rate (CFR) and the development of adverse events in patients positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Mexican population.

Materials and methods

We analyzed the data from 13,842 laboratory-confirmed SARS-CoV-2 patients in Mexico between January 1, 2020, and April 25, 2020. We investigated the risk of death and the development of adverse events (hospitalization, pneumonia, orotracheal intubation, and intensive care unit [ICU] admission), comparing the number of comorbidities of each patient.

Results

The patient mean age was 46.6 ± 15.6 years, 42.3% (n = 5853) of the cases were women, 38.8% of patients were hospitalized, 4.4% were intubated, 29.6% developed pneumonia, and 4.4% had critical illness. The CFR was 9.4%. The risk of hospitalization (odds ratio [OR] = 3.1, 95% confidence interval [CI]: 2.7-3.7), pneumonia (OR = 3.02, 95% CI: 2.6-3.5), ICU admission (OR = 2, 95% CI: 1.5-2.7), and CFR (hazard ratio = 3.5, 95% CI: 2.9-4.2) was higher in patients with three or more comorbidities than in patients with 1, 2, or with no comorbidities.

Conclusions

The number of comorbidities may be a determining factor in the clinical course and its outcomes in SARS-CoV-2-positive patients.

Authors+Show Affiliations

Emergency Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico City, Mexico. Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico.Emergency Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico City, Mexico.Department of Endocrinology, Obesity Clinic, INCMNSZ, Mexico City, Mexico.Deparment of Biochemistry and Foods, Faculty of Chemical Sciences, Benemérita Universidad Autónoma de Puebla, Pue., Mexico.Deparment of Biochemistry and Foods, Faculty of Chemical Sciences, Benemérita Universidad Autónoma de Puebla, Pue., Mexico.Department of Nutrition and Public Health, Faculty of Health and Food Sciences, "Programa Universidad Bío-Bío (UBB) Saludable," Universidad del Bío-Bío, Concepción, Chile.Deparment of Biochemistry and Foods, Faculty of Chemical Sciences, Benemérita Universidad Autónoma de Puebla, Pue., Mexico.Deparment of Biochemistry and Foods, Faculty of Chemical Sciences, Benemérita Universidad Autónoma de Puebla, Pue., Mexico.

Pub Type(s)

Journal Article
Multicenter Study
Observational Study

Language

eng

PubMed ID

32584330

Citation

Kammar-García, Ashuin, et al. "IMPACT of COMORBIDITIES in MEXICAN SARS-COV-2-POSITIVE PATIENTS: a RETROSPECTIVE ANALYSIS in a NATIONAL COHORT." Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion, vol. 72, no. 3, 2020, pp. 151-158.
Kammar-García A, Vidal-Mayo JJ, Vera-Zertuche JM, et al. IMPACT OF COMORBIDITIES IN MEXICAN SARS-COV-2-POSITIVE PATIENTS: A RETROSPECTIVE ANALYSIS IN A NATIONAL COHORT. Rev Invest Clin. 2020;72(3):151-158.
Kammar-García, A., Vidal-Mayo, J. J., Vera-Zertuche, J. M., Lazcano-Hernández, M., Vera-López, O., Segura-Badilla, O., Aguilar-Alonso, P., & Navarro-Cruz, A. R. (2020). IMPACT OF COMORBIDITIES IN MEXICAN SARS-COV-2-POSITIVE PATIENTS: A RETROSPECTIVE ANALYSIS IN A NATIONAL COHORT. Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion, 72(3), 151-158. https://doi.org/10.24875/RIC.20000207
Kammar-García A, et al. IMPACT of COMORBIDITIES in MEXICAN SARS-COV-2-POSITIVE PATIENTS: a RETROSPECTIVE ANALYSIS in a NATIONAL COHORT. Rev Invest Clin. 2020;72(3):151-158. PubMed PMID: 32584330.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - IMPACT OF COMORBIDITIES IN MEXICAN SARS-COV-2-POSITIVE PATIENTS: A RETROSPECTIVE ANALYSIS IN A NATIONAL COHORT. AU - Kammar-García,Ashuin, AU - Vidal-Mayo,José de J, AU - Vera-Zertuche,Juan M, AU - Lazcano-Hernández,Martín, AU - Vera-López,Obdulia, AU - Segura-Badilla,Orietta, AU - Aguilar-Alonso,Patricia, AU - Navarro-Cruz,Addi R, PY - 2020/6/26/entrez PY - 2020/6/26/pubmed PY - 2020/7/4/medline KW - Adverse events KW - Comorbidities KW - Coronavirus disease 2019 KW - Demographic characteristic KW - Mortality KW - Severe acute respiratory syndrome coronavirus 2 SP - 151 EP - 158 JF - Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion JO - Rev Invest Clin VL - 72 IS - 3 N2 - Background: The coronavirus disease 2019 outbreak is a significant challenge for health-care systems around the world. Objective: The objective of the study was to assess the impact of comorbidities on the case fatality rate (CFR) and the development of adverse events in patients positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Mexican population. Materials and methods: We analyzed the data from 13,842 laboratory-confirmed SARS-CoV-2 patients in Mexico between January 1, 2020, and April 25, 2020. We investigated the risk of death and the development of adverse events (hospitalization, pneumonia, orotracheal intubation, and intensive care unit [ICU] admission), comparing the number of comorbidities of each patient. Results: The patient mean age was 46.6 ± 15.6 years, 42.3% (n = 5853) of the cases were women, 38.8% of patients were hospitalized, 4.4% were intubated, 29.6% developed pneumonia, and 4.4% had critical illness. The CFR was 9.4%. The risk of hospitalization (odds ratio [OR] = 3.1, 95% confidence interval [CI]: 2.7-3.7), pneumonia (OR = 3.02, 95% CI: 2.6-3.5), ICU admission (OR = 2, 95% CI: 1.5-2.7), and CFR (hazard ratio = 3.5, 95% CI: 2.9-4.2) was higher in patients with three or more comorbidities than in patients with 1, 2, or with no comorbidities. Conclusions: The number of comorbidities may be a determining factor in the clinical course and its outcomes in SARS-CoV-2-positive patients. SN - 0034-8376 UR - https://www.unboundmedicine.com/medline/citation/32584330/IMPACT_OF_COMORBIDITIES_IN_MEXICAN_SARS_COV_2_POSITIVE_PATIENTS:_A_RETROSPECTIVE_ANALYSIS_IN_A_NATIONAL_COHORT_ DB - PRIME DP - Unbound Medicine ER -